Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2024 | $18.00 | Outperform | Leerink Partners |
| 3/26/2024 | Market Perform → Outperform | TD Cowen | |
| 11/20/2023 | Neutral | JP Morgan | |
| 7/25/2023 | Outperform → Market Perform | TD Cowen | |
| 5/1/2023 | $9.00 → $12.00 | Underperform → Neutral | BofA Securities |
| 4/26/2023 | $24.00 | Buy | Canaccord Genuity |
| 1/6/2023 | $22.00 → $9.00 | Buy → Underperform | BofA Securities |
| 10/24/2022 | $30.00 | Mkt Perform → Outperform | SVB Leerink |
10-Q - Stoke Therapeutics, Inc. (0001623526) (Filer)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
S-3ASR - Stoke Therapeutics, Inc. (0001623526) (Filer)
SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13D/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)
– Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification – – Phase 1/2a ADMIRAL Study Data STK-001 (70mg): Patients treated with 2 or 3 initial doses experienced substantial and sustained reductions in convulsive seizure frequency; Median reductions at 3 months after last dose (n=6) of 80% and 89% (n=3) at 6 months after last dose, compared to baseline – – OLE Study Data STK-001 (30mg, 45mg): Sustained reductions in convulsive seizure frequency and improvements in cognition and behavior – – MONARCH & ADMIRAL
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will hold a webinar and conference call for analysts and investors at 8:00 a.m. Eastern Time on Tuesday, July 25, 2023, to present new data from the two ongoing Phase 1/2a studies (MONARCH and ADMIRAL) and the SWALLOWTAIL open-label extension study in children and adolescents with Dravet syndrome. The webinar will be broadcast live on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Participants who want to join the call and ask
– Company announces positive interim data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome – – Single and multiple doses of STK-001 up to 45mg were well-tolerated – – 55% median reduction from baseline in convulsive seizure frequency was observed among patients treated with three doses of 45mg – – In 2023 the Company plans to report data from more patients treated with multiple doses of 45mg as well as those treated with multiple doses of 70mg – – As of September 30, 2022, Company had $252.2 million in cash, cash equivalents, marketable securities, and restricted cash, anticipated to fund operations into 2025 – – Management will h
– Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently annou
– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
Wedbush analyst Laura Chico reiterates Stoke Therapeutics (NASDAQ:STOK) with a Outperform and maintains $17 price target.
Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Stoke Therapeutics, revealing an average target of $24.2, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 3.2% decline, the current aver
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.
Leerink Partners resumed coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $18.00
TD Cowen upgraded Stoke Therapeutics from Market Perform to Outperform
JP Morgan resumed coverage of Stoke Therapeutics with a rating of Neutral
– Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in studies of zorevunersen by year-end – – Discussions with FDA and global regulatory agencies related to a single global Phase 3 study of zorevunersen continue to progress; Company to provide an update by year-end – – As of September 30, 2024, Company had $269.2 million in cash, cash equivalents, and marketable securities – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today reported financial results for the third qu
– New data showed improvements in cognition and behavior during the first year of treatment with additional increases demonstrated as treatment continued – – Clinical effects observed across the Phase 1/2a and open-label extension studies (OLEs) of zorevunersen are a first in the treatment of Dravet syndrome and support plans for the Company's Phase 3 registrational study – – Zorevunersen generally well-tolerated across the studies – – Data presented for the first time at the 15th European Epilepsy Congress (EEC) – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announce
– Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol